Evidence map›Paper›PMID 39652575›Full record

ArticleCancer research2025

HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma.

Rigney E Turnham, Adriana Pitea, Gwendolyn M Jang, Zhong Xu, Huat Chye Lim, Alex L Choi, John Von Dollen, Rebecca S Levin, James T Webber, Elizabeth McCarthy and 17 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Rigney E Turnham *Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0009-0004-7483-6350
Adriana Pitea *Department of Medicine, University of California, San Diego, La Jolla, California.ORCID 0009-0000-6467-6542
Gwendolyn M JangQuantitative Biosciences Institute, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7806-9874
Zhong XuDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7565-6053
Huat Chye LimDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8161-1847
Alex L ChoiDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0009-0001-6522-4924
John Von DollenQuantitative Biosciences Institute, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8430-7848
Rebecca S LevinDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California.ORCID 0009-0005-9770-3216
James T WebberDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8594-9888
Elizabeth McCarthyDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-0073-4069
Junjie HuDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1188-5399
Xiaolei LiDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5143-1810
Li CheDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7971-8725
Ananya SinghDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0009-0005-0776-4657
Alex YoonDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0009-0005-1819-5592
Gary K L ChanDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8450-7831
Robin K KelleyDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1984-2430
Danielle L SwaneyQuantitative Biosciences Institute, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-6119-6084
Wei ZhangDepartment of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-0942-1245
Sourav BandyopadhyayDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3120-923X
Fabian J TheisTUM School of Life Sciences, Technical University of Munich, Munich, Germany.ORCID 0000-0002-2419-1943
Manon EckhardtQuantitative Biosciences Institute, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8143-6129
Xin ChenDepartment of Bioengineering, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-9588-0164
Kevan M ShokatQuantitative Biosciences Institute, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8590-7741
Trey IdekerDepartment of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-1708-8454
Nevan J KroganQuantitative Biosciences Institute, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4902-337X
John D GordanDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8997-5725

Funding

TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2012 to 2024
$17.3M
The Cancer Cell Map Initiative v2.0U54CA274502 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emma Lundberg · 2022 to 2026
$14.2M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2017 to 2021
$10.9M
NRSA Training CoreTL1TR001871 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SOMSOUK, MA · 2016 to 2025
$10.1M
Molecular Genetics of Liver CancersR01CA136606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2009 to 2016
$2.6M
Signaling cascades in cholangiocarcinoma developmentR01CA190606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2016 to 2020
$1.8M
American Cancer Society (ACS)Burroughs Wellcome Fund (BWF)Center for Cancer Research (CCR) R01CA136606Center for Cancer Research (CCR) R01CA190606Center for Cancer Research (CCR) U54CA209891Conquer Cancer Foundation (CCF)Hope Funds for Cancer Research (HFCR) HCFR-21-05-05Howard Hughes Medical InstituteJoachim Herz Stiftung (Joachim Herz Foundation)National Cancer Institute (NCI) RO1CA130699National Center for Advancing Translational Sciences (NCATS) TR001871NCATS NIH HHS TL1 TR001871NCI NIH HHS R01 CA136606NCI NIH HHS R01 CA190606NCI NIH HHS U54 CA209891NCI NIH HHS U54 CA274502NIGMS NIH HHS P41 GM103504
6 · The paper itself

Abstract

Hepatitis B virus (HBV) infections promote liver cancer initiation by inducing inflammation and cellular stress. Despite a primarily indirect effect on oncogenesis, HBV is associated with a recurrent genomic phenotype in hepatocellular carcinoma (HCC), suggesting that it impacts the biology of established HCC. Characterization of the interaction of HBV with host proteins and the mechanistic contributions of HBV to HCC initiation and maintenance could provide insights into HCC biology and uncover therapeutic vulnerabilities. In this study, we used affinity purification mass spectrometry to comprehensively map a network of 145 physical interactions between HBV and human proteins in HCC. A subset of the host factors targeted by HBV proteins were preferentially mutated in non-HBV-associated HCC, suggesting that their interaction with HBV influences HCC biology. HBV interacted with proteins involved in mRNA splicing, mitogenic signaling, and DNA repair, with the latter set interacting with the HBV oncoprotein X (HBx). HBx remodeled the PP2A phosphatase complex by excluding striatin regulatory subunits from the PP2A holoenzyme, and the HBx effects on PP2A caused Hippo kinase activation. In parallel, HBx activated mTOR complex 2, which can prevent YAP degradation. mTOR complex 2-mediated upregulation of YAP was observed in human HCC specimens and mouse HCC models and could be targeted with mTOR kinase inhibitors. Thus, HBV interaction with host proteins rewires HCC signaling rather than directly activating mitogenic pathways, providing an alternative paradigm for the cellular effects of a tumor-promoting virus. Significance: Integrative proteomic and genomic analysis of HBV/host interactions illuminated modifiers of hepatocellular carcinoma behavior and key signaling mechanisms in advanced disease, which suggested that HBV may have therapeutically actionable effects.

Indexed as

Carcinoma, HepatocellularHepatitis BHepatitis B virusLiver NeoplasmsProtein Phosphatase 2AnimalsHumansMiceProtein Serine-Threonine KinasesSignal TransductionTrans-ActivatorsViral Regulatory and Accessory Proteinshepatitis B virus X proteinProtein Phosphatase 2Protein Serine-Threonine KinasesTrans-ActivatorsViral Regulatory and Accessory Proteins

Identifiers

PMID39652575
PMCPMC11949624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.